Pan, D.; Du, L.; Liu, J.; Kuerban, K.; Huang, X.; Wang, Y.; Guo, Q.; Chen, H.; Wang, S.; Wang, L.;
et al. In Situ Vaccination with a Vpr-Derived Peptide Elicits Systemic Antitumor Immunity by Improving Tumor Immunogenicity. Vaccines 2025, 13, 710.
https://doi.org/10.3390/vaccines13070710
AMA Style
Pan D, Du L, Liu J, Kuerban K, Huang X, Wang Y, Guo Q, Chen H, Wang S, Wang L,
et al. In Situ Vaccination with a Vpr-Derived Peptide Elicits Systemic Antitumor Immunity by Improving Tumor Immunogenicity. Vaccines. 2025; 13(7):710.
https://doi.org/10.3390/vaccines13070710
Chicago/Turabian Style
Pan, Danjie, Ling Du, Jiayang Liu, Kudelaidi Kuerban, Xuan Huang, Yue Wang, Qiuyu Guo, Huaning Chen, Songna Wang, Li Wang,
and et al. 2025. "In Situ Vaccination with a Vpr-Derived Peptide Elicits Systemic Antitumor Immunity by Improving Tumor Immunogenicity" Vaccines 13, no. 7: 710.
https://doi.org/10.3390/vaccines13070710
APA Style
Pan, D., Du, L., Liu, J., Kuerban, K., Huang, X., Wang, Y., Guo, Q., Chen, H., Wang, S., Wang, L., Zhou, P., Meng, Z., & Ye, L.
(2025). In Situ Vaccination with a Vpr-Derived Peptide Elicits Systemic Antitumor Immunity by Improving Tumor Immunogenicity. Vaccines, 13(7), 710.
https://doi.org/10.3390/vaccines13070710
